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Abstract
Breast cancer is a common malignancy worldwide. It is considered top cancer in
women and about 13% of women in the general population will develop breast cancer
sometimes during their lives, with a gradual increase in incidence as survival
increases. Primary prevention of breast cancer is directed toward promoting a healthy
lifestyle and reversing modifiable risk factors; these factors include smoking cessa-
tion, physical activity, alcohol, and dietary modification. Imaging plays an important
role in the diagnosis and management of breast cancer, it is also considered the most
valuable tool in screening breast cancer. Mammogram is the most widely used
method; it is recommended by many societies and committees as a useful method for
early detection of breast cancer. False-positive and over-diagnosis constitute a prob-
lem in using screening mammogram. The implementation of a screening program
faces many issues that may adversely affect its success such as personal factors, social
factors, and accessibility issues. These issues should be identified as the initial step in
program implementation. The role of Magnetic Resonance Imaging and Ultrasound is
mainly in high-risk patients. The introduction of Artificial Intelligence in Mammo-
gram may add beneficial effects in time and efforts improving its efforts.
Keywords: breast cancer, screening, mammogram, breast self-examination,
breast ultrasound
1. Introduction
Breast cancer is a common malignancy worldwide. It is considered top cancer in
women and about 13% of women in the general population will sometimes develop
breast cancer during their lives, with gradual increase in incidence as survival
increases [1]. That is the reason why Breast cancer prevention is the core of many
researches and trials worldwide. The World health organization has recommended
breast self-examination, mammography as an effective screening tool since 2007.
As in conclusion, early detection of breast cancer (secondary prevention) remains
the cornerstone for breast cancer control [2].
Educating the population about eliminating modifiable risk factors (e.g.
smoking, obesity) remains essential in the primary prevention of breast cancer [3].
1.1 Age
As a rule of thumb, breast cancer shows an increase in incidence as the age
increases, about 8 in 10 cases of breast cancer occurs in women aged 50 or above [4].
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However, this may not be applicable for all countries, as a study done by Mutar et al.
shows that 45% percent of breast cancer patients were younger than 50 years [5].
The disease is extremely rare before the 20s, and it is as highly prevalent as 20%
at age of 80 [6]. It is important to mention that the age may be the only risk factor
present in a woman who develops breast cancer [7].
1.2 Hormonal factors
It is proposed that the longer a woman is exposed to cycling reproductive
hormones, the higher the risk of breast cancer disease [8].
1.2.1 Time of menarche and menopause
In a large meta-analysis study done in 2012 [9]. An apparent association was
found between the early age of menarche and the late age of menopause and breast
cancer development, with the first factor being a stronger independent factor for
breast cancer development.
In addition to that, these two factors seem to play a more complex role; they
favor the development of estrogen-receptor positive disease & lobular histological
type of breast cancer.
1.2.2 Parity, breastfeeding and age of having a first child
Breast cancer is more common in nulliparous women and breastfeeding, in
particular, appears to be a protective factor. Also, having the first child at an early
age seems to be protective [6].
Increasing parity was associated with a pronounced decrease in the risk of breast
cancer, with each extra birth granting about 10 percent reduction of breast cancer
risk, and the disease is 13 times more common for each five years increment in the
age of having the first child [10].
And just like the effect of menarche & menopause, these factors not merely
affect the duration of hormonal exposure but also the hormonal receptor status of
breast cancer; for example, breastfeeding is inversely associated with hormone
receptor-negative breast cancers and parous women were shown to have a lower
risk of estrogen-positive breast cancer [11].
1.2.3 Contraceptive pills
Current or recent use of oral contraceptive pills increases the relative risk of
breast cancer [12].
Post-menopausal hormonal replacement therapy (HRT) was associated with
an increased risk for breast cancer [13]. Vaginal estrogens are considered an
exception [4].
1.2.4 Obesity
Breast cancer is more common in obese women [6]. Obesity also affects breast
cancer management; obese patients have lower treatment efficacy, more
complications and higher recurrence rates [14].
Again, this supports the theory of linking breast cancer to the high estrogen
states.
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1.3 Lifestyle
1.3.1 Physical activity
A study held among Chinese women showed evidence that physical activity
decreases breast cancer incidence; this is maybe due to the proposed effect of
exercise on estrogen & insulin [15]. Education about this aspect seems reasonable
for breast cancer prevention in high-risk groups.
1.3.2 Smoking
Both passive & active smoking are associated with an increased risk of breast
cancer [16].
Also, women who were smoking at the time of their diagnosis have weaker
outcomes and poorer survival [17]. However, there are inconclusive results about
the smoking risk for the recurrence of the disease.
1.3.3 Alcohol
Just like smoking, it does increase the risk for breast cancer even in light to
moderate intake in all ethnicities & with no association to estrogen hormonal
status [18].
1.3.4 Dietary factors
Meat, caffeine, high fat diet, Low phytoestrogen all appear to increase the risk of
breast cancer, in contrast to increment in vitamin D and calcium levels [6, 19].
1.3.5 Others
Living in stressful life/personality may appear to increase the breast cancer
risk [20].
1.4 Drugs and radiation
• Non-steroidal anti-inflammatory drugs may appear to protect against breast
cancer, although the evidence is not strong [21].
• Digoxin carries more pronounced research evidence to increase the risk of
breast cancer, and all women should be informed about this relative risk before
starting treatment [20, 22, 23]. This usually describes its use for more than
four years and the risk is elevated by 21 to 40%.
• Radiation: patient’s receiving radiotherapy as part of their treatment of
Hodgkin lymphoma appeared to have an increased risk for breast cancer [6].
Routine chest X-ray and Computed tomography scans only have a little
contribution to the risk [4].
2. Imaging in oncology
The first imaging modality to be discovered was X-ray by the German physicist




amputated leg by German Surgeon Konig. the second imaging modality involved in
oncology was ultrasonography, which was used for brain tumors, it Dussik used and
called (hyper phonography) [24, 25]. The ultrasonography was then used in bowel,
breast and obstetrics.
The history of mammography in breast cancer began in 1913 by Salomon who used
it to evaluate 3000 mastectomies specimens [26]. He evaluated the role of radiological
assessment correlated with the macrocalcifications and microscopic assessment of
breast in order to differentiate between benign and malignant diseases [27].
The use of Xeromammography in 1960s shows improvement in
mammogram diagnostic ability, the 1970s and 80s were the time to establish of
screening mammography. In 1996 the Food and Drug Administration (FDA)
established guidelines for commercializing digital mammography equipment [27].
Offering a screening mammography started in different times according to each
country, for example, Australia had started screening by mammography every
2 years for women aged 50–69 years since 1991, while in Europe it started in 1986
[28, 29].
3. Screening
Screening is applied to many types of cancer, including mainly breast,
colorectal, prostate, cervical and lung cancer. Breast cancer screening includes
three main types screening mammography, clinical examination and ultrasound
[30, 31].
Mammography is the most common screening modality for detecting breast
cancers in asymptomatic women. The age and the frequency for screening mam-
mogram is the subject of ongoing debate [32]. There is a considerable disagreement
between guidelines regarding the recommendation for the age and frequency this
might results from the wide variation in studies as found by Raichand et al. [32]. In
a meta-analysis of 11 randomized clinical trials, the relative risk RR of breast cancer
mortality for screening compared with controls was 080 (95% CI 073–089), with
a 20% relative risk reduction [33].
The starting of ‘Europe against Cancer’ program in 1986, has led the committee
of experts to start systematic population-based screening for cancer that shows
decreased mortality with implementation. The effectiveness and benefits of mam-
mography screening have been evaluated in randomized trials that showed
decreased mortality by 20–35% in women 50–69 year [34].
If breast cancer is not diagnosed, the screening result is considered false-positive
resulting in distress and anxiety among women [35]. The rates of false-positive
results depend on many factors including screening interval, single versus double
reading, sensitivity of the performance, participation patterns, equipment, and
characteristics of the screening population [36]. Women who had false-positive
results had a twofold increased risk of a later screen-detected cancer and might
cause a reduced likelihood of reattendance [36, 37]. A recent meta-analysis had
shown that a previous false-positive test does not influence participation in
subsequent screening program [38].
It might better to encourage women with false-positive results to participate in
regular screening, as the potential benefit is higher than in women who had nega-
tive tests [36].
The elements suggestive of a successful screening program are substantial
reduction in cancer-related mortality, good participants’ compliance, acceptability
among participants, coverage, and high reattendance rate [37, 39].
Box 1 conditions required for successful mammogram screening.
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3.1 Barriers to participating in mammogram
3.1.1 Personal beliefs
Fear of a positive result, pain and embarrassment related to the procedure, lack
of knowledge about breast cancer and its screening, absence of trust in doctors and
hospitals, lack of knowledge regarding mammography and its advantages,
perception of being healthy, and fear of radiation exposure.
3.1.2 Accessibility and associated factors
Low-income population and lack of resources and health insurance, cost of
mammogram, language barrier for minorities, lack of time required for mammo-
gram, lack of transportation including personal and public transport, registration
difficulties, and lower educational level.
3.1.3 Social factors
Lack of medical recommendation and advice regarding mammogram and
discouragement from other people.
Other factors that affect participation include Age, Religiosity, family and
personal history, and role of responsibility [41, 42].
3.2 Benefits and harms of breast cancer screening
Breast cancer mortality is generally reduced with mammography screening,
although the magnitudes of effect are small. Advanced cancer is reduced with
screening for women aged 50 years or older [43].
1. It requires sufficient health system as well as financial resources to achieve a sustainable program
with effective diagnostic and treatment capabilities including equipment, infrastructure, quality
assurance, and monitoring processes.
2. It requires an administrative facilities responsible for the process of implementation and evaluation.
3. It requires validated protocols for screening steps, including recognizing the target population,
inviting women who are eligible to be screened, applying screening tests, referral mechanism and its
regulations, and management of each case accordingly.
4. It requires a good Communication and education of eligible women using culturally appropriate,
objective information about the benefits and harms of breast cancer screening.
5.Ensuring good adherence to the guidelines for screening, diagnosis and treatment which are
evidence based.
6. Information system for recording data of the screening process like calling the participants for follow
up if abnormality was detected on screening.
7.Continuous regular monitoring, assessment and reporting of program performance and impact
depending on reliable indicators like women’s safety and satisfaction [40].
Box 1.




The detection of breast cancer in Australia increased in 2004 and mortality
decreased [28]. On the other hand, possible harms of breast cancer screening may
be related to false-positive results. According to a study published in 2011, most
abnormal mammograms are actually false-positive. Follow-up testing adds
additional cost [44].
3.3 Breast cancer overdiagnosis
The effectiveness of screening is mainly dependent on detecting cancer at early
stage to promote early detection and better outcome, however, screening yields
malignancies that may not have progressed during lifetime [45]. the lead time is the
period between detection of cancer at screening and when it might be presented
clinically, with stopping screening, the cancer incidence must fall, and at the end of
screening time plus lead time, the cumulative incidence of the controlled and the
screened populations should be the same. During the screening, some cancer
detected might never progress throughout woman’s life and might die from another
cause before cancer becomes clinically detected. In another word overdiagnosis is
defined as “detection of cancers that would never have been found without
screening” [46–51] (Tables 1 and 2).
3.4 Clinical Breast examination (CBE)
Benefits: The current evidence does not support additional benefits and harms
of CBE due to lack of evidence. CBE accuracy in the community screening might be
lower than in the RCT [53].
Harms:
• False positives with additional testing and anxiety.
• False negatives with potential false reassurance and delay in cancer diagnosis.
3.5 Breast self-examination (BSE)
Benefits: BSE has been compared with no screening and has been shown to have
no benefit in reducing breast cancer mortality [53].
Harms: There is solid evidence that formal instruction and encouragement to




Low (L) risk Category 1 breast density without or with only one risk factor (family history or
breast biopsy) or
Category 2 breast density with no risk factors
Medium-Low
(ML) risk
Category 1 breast density with two additional risk factors, Category 2 breast




Category 2 breast density with two additional risk factors, or Categories 3 or 4
breast density with only one risk factor
High (H) risk Categories 3 or 4 breast density with two additional risk factors
Table 1.
Risk stratification for breast cancer screening. It is adopted from Yamamuro et al. [47].
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U.S: United state, ECIBC, GDG: The European Commission Initiative on Breast Cancer Guidelines Development Group.
Table 2.

























lesions. The biopsy rate was 1.8% among the study population compared with 1.0%
among the control group.
3.6 Magnetic resonance imaging (MRI)
MRI has the greatest sensitivity of all imaging techniques, and it is considered a
problem-solving modality, as a negative breast MRI can exclude malignancy. Only
microcalcification seen on mammography cannot be excluded sufficiently by MRI
and mammography in such case should be used to judge for biopsy indications. The
role of MRI in screening high-risk patients is established, the sensitivity of MRI in
high risk patients is between 71 and 100% compared with 16–40% in mammogra-
phy, while specificity ranges 81–99% for MRI and 93–99% in mammography [54].
The American Cancer Society Guidelines recommends annual breast MRI
screening starting from 25 to 30 years in women with a first-degree relative with a
BRCA mutation, patients with a BRCA gene mutation, and women with 25% or
greater lifetime risk of cancer [55].
European Society of Breast Imaging also advises annual screening with MRI for
patients with breast cancer diagnosed under 50 years of age who have a 20%
lifetime risk of recurrence and for patients who received radiation to the chest in
their second or third decade of life and for patients with inherited syndromes, like
Cowden and LiFraumeni syndrome, and their first-degree relatives [54].
Starting Screening at age 40 years may provide some benefits in average-risk
populations, but offer higher levels of harm than strategies initiated at age 50 years.
The age for cessation of screening can be based on the Comorbidity levels. Biennial
screening strategies can be used and considered as the most efficient, but annual
screening might be indicated from 40 to 74 years of age in groups with have a 2- to
4-fold higher risk than average [56].
3.7 Ultrasound (US)
Until the early 1990’s, breast ultrasound was used primarily to distinguish solid
from cystic lesions and image-guided interventions [57]. Ultrasound can be added
to mammography in women with dense breasts so that, to increase the sensitivity of
detecting the cancer. Ultrasound has relatively good specificity and sensitivity as a
follow up tool in women with dense breast and negative mammogram, for that
reason, ultrasound can be considered as an adjunct to mammography in screening
women with dense breasts [58]. One meta-analysis results suggest the addition of
US to mammography of women with dense breasts improves the sensitivity of
detecting breast cancer, despite a slightly decreased specificity. Follow-up US also
had good diagnostic sensitivity and specificity [59].
Ultrasound, when compared to mammography, is radiation-free, cheaper and
less strenuous modality [60].
Using mammography alone for screening has been shown to have poorer diag-
nostic performance for high-risk women than when used for the general population.
For high-risk women, mammography has lower sensitivity and a higher interval
cancers rate that might be spread to the lymph nodes. Many factors described in the
literature may be responsible for that; like higher breast density, younger age of
onset, and increased tumor growth, breast cancer associated with genetic mutation
may also be invisible on screening mammography. Supplemental screening with
(MRI) significantly improves the detection rate of breast cancer in high-risk
populations, compared to mammography alone. Ultrasound may be used instead in
patients with a contraindication of MRI due to anxiety or severe claustrophobia, or




3.8 Artificial intelligence in breast screening
Computer-aided detection software for mammography was intimated in 1990s
and since that improvement had been made to improve outcomes. The use of artifi-
cial intelligence in screening mammogram has been shown to provide an absolute
reduction of 1.2–5.7% in false positives and 2.7–9.4% in false negatives [62]. Artificial
intelligence use in screening has the potential advantages of reducing the interval
cancer rate without any additional modality, the reduction in interval cancer risk is an
important indicator for screening program efficacy [63]. The use of AI in screening
requires acceptance to participate and trust in their results, many people as shown by
Ongena et al. [64] do not supply the use of AI alone in screening.
4. Conclusions
As breast cancer is among the most common cancer in women, prevention repre-
sents an important step to decreasemorbidity andmortality. Prevention can be applied
on three levels primary, secondary, and tertiary. Screening mammogram has the main
advantage of early detection leading to better management and decreased mortality.
Acknowledgements
Authors want to thank their family and friends, particularly Tareq Mutar,
Seemaa Albahrani, Zahraa Mutar, Reem Alsaad, Majid Hameed, Akhlass Al-naiemi,
Saleh Goyani, Siham Jalal, Hamed Obaid, Fatima Khadem, Batool Ali Ghalib.
Conflict of interest
The authors declare no conflict of interest.
Notes/thanks/other declarations
Place any other declarations, such as “Notes”, “Thanks”, etc. in before the
References section. Assign the appropriate heading. Do NOT put your short
biography in this section. It will be removed.
Author details
Mohammed Tareq Mutar1*, Mustafa Majid Hameed1, Mohammed Saleh Goyani1,
Aqeel Shakir Mahmood1 and Abo-Alhasan Hammed Obaid2
1 Department of Surgery, College of Medicine, University of Baghdad, Iraq
2 Department of Surgery, College of Medicine, Almustansrya University, Iraq
*Address all correspondence to: muhammed.tariq64@gmail.com
©2021 TheAuthor(s). Licensee IntechOpen. This chapter is distributed under the terms
of theCreativeCommonsAttribution License (http://creativecommons.org/licenses/
by/3.0),which permits unrestricted use, distribution, and reproduction in anymedium,
provided the original work is properly cited.
12
Breast Cancer - Evolving Challenges and Next Frontiers
References
[1]Howlader N, Noone AM, Krapcho M,
et al. SEER Cancer Statistics Review,
1975–2017, National Cancer Institute.
Bethesda, MD. Available at https://seer.
cancer.gov/csr/1975_2017.
[2] Breast cancer prevention and control:
Early Detection. Available at: https://
www.who.int/cancer/detection/
breastcancer/en/
[3] Edward R. Sauter. Breast Cancer
Prevention: Current Approaches and
Future Directions.Eur J Breast Health.
2018 Apr; 14(2): 64–71. doi: 10.5152/
ejbh.2018.3978
[4]National health service (NHS),
available at: https://www.nhs.uk/
conditions/breast-cancer/causes/.
[5]Mutar MT, Goyani MS, Had AM,
Mahmood AS. Pattern of Presentation of
Patients With Breast Cancer in Iraq in
2018: A Cross-Sectional Study. J Glob
Oncol. 2019 Nov;5:1-6. doi: 10.1200/
JGO.19.00041. PMID: 31721627;
PMCID: PMC6882514.
[6] Bailey and Love's Short Practice of
Surgery; 27th edition. N. S. Williams, C.
J. K. Bulstrode and P. R. O' Connell.
Boca Raton, FL: CRC Press, 2018.
[7] Center for disease control,breast
cancer risk factors, available at https://
www.cdc.gov/cancer/breast/basic_info/
risk_factors.htm
[8] Kara Britt, Menarche, menopause,





[9] Collaborative Group on Hormonal
Factors in Breast Cancer.Menarche,
menopause, and breast cancer risk:
individual participant meta-analysis,
including 118 964 women with breast
cancer from 117 epidemiological studies.
Lancet Oncol. 2012 Nov; 13(11): 1141–
1151. doi: 10.1016/S1470-2045(12)
70425-4
[10] Lambe M, Hsieh CC, Chan HW,
Ekbom A, Trichopoulos D, Adami HO.
Parity, age at first and last birth, and
risk of breast cancer: a population-based
study in Sweden. Breast Cancer Res
Treat. 1996;38(3):305-311. doi: 10.1007/
BF01806150. PMID: 8739084.
[11] Fortner, R.T., Sisti, J., Chai, B. et al.
Parity, breastfeeding, and breast cancer
risk by hormone receptor status and
molecular phenotype: results from the
Nurses’ Health Studies. Breast Cancer
Res 21, 40 (2019). https://doi.org/
10.1186/s13058-019-1119-y
[12] Bhupathiraju SN, Grodstein F,
Stampfer MJ, et al. Exogenous hormone
use: Oral contraceptives,
postmenopausal hormone therapy, and
health outcomes in the Nurses' Health
Study. American Journal of Public
Health 2016; 106(9):1631-1637
[13] Vinogradova Y, Coupland C,
Hippisley-Cox J. Use of hormone
replacement therapy and risk of breast
cancer: nested case-control studies using
the QResearch and CPRD databases.
BMJ. 2020 Oct 28;371:m3873. doi:
10.1136/bmj.m3873.
[14] Kyuwan Lee, Laura Kruper,
Christina M. Dieli-Conwright, and
Joanne E. Mortimer. The Impact of
Obesity on Breast Cancer Diagnosis and
Treatment. 2019. Curr Oncol Rep. 2019;
21(5): 41. doi: 10.1007/s11912-019-
0787-1
[15]Gao Y, Huang YB, Liu XO, Chen C,
Dai HJ, Song FJ, et al. Tea consumption,
alcohol drinking and physical activity
associations with breast cancer risk
among Chinese females: a systematic
review and meta-analysis. Asian Pacific





[16] Rosenberg L, Boggs DA, Bethea TN,
Wise LA, Adams-Campbell LL, Palmer
JR. A prospective study of smoking and
breast cancer risk among African-
American women. Cancer causes &
control : CCC. 2013;24(12):2207–2215.
Epub 2013/10/03.
[17] Berube S, Lemieux J, Moore L,
Maunsell E, Brisson J. Smoking at time
of diagnosis and breast cancer-specific
survival: new findings and systematic
review with meta-analysis. Breast
cancer research : BCR. 2014;16(2):R42.
Epub 2014/04/22.
[18] Park SY, Kolonel LN, Lim U, White
KK, Henderson BE, Wilkens LR.
Alcohol consumption and breast cancer
risk among women from five ethnic
groups with light to moderate intakes:
the Multiethnic Cohort Study.
International journal of cancer Journal
international du cancer. 2014;134(6):
1504–1510. Epub 2013/09/17.
[19] Seyed Hesam Bani Hashemi, Samieh
Karimi, and Hamidreza Mahboobi.
Lifestyle changes for prevention of breast
cancer Electron Physician. 2014 Jul-Sep; 6
(3): 894–905. doi: 10.14661/2014.894-905
[20] Butow PN, Hiller JE, Price MA,
Thackway SV, Kricker A, Tennant CC.
Epidemiological evidence for a
relationship between life events, coping
style, and personality factors in the
development of breast cancer. Journal of
psychosomatic research. 2000;49(3):
169–181. Epub 2000/12/09
[21]Zhao YS, Zhu S, Li XW,Wang F, Hu
FL, Li DD, et al. Association between
NSAIDs use and breast cancer risk: a
systematic review and meta-analysis.
Breast cancer research and treatment.
2009;117(1):141–50. Epub 2008/11/04.
[22] Ahern TP, Tamimi RM, Rosner BA,
Hankinson SE. Digoxin use and risk of
invasive breast cancer: evidence from
the Nurses’ Health Study and meta-
analysis. Breast cancer research and
treatment. 2014;144(2):427–435. Epub
2014/02/28.
[23]Mathur P, Sathishkumar K,
Chaturvedi M, Das P , Sudarshan KL,
Santhappan S Cancer Statistics, 2020:
Report From National Cancer Registry
Programme, India. J Glob Oncol. 2020;6:
1063-1075. DOI: 10.1200/GO.20.00122
[24] Shampo, Marc A.; Kyle, Robert A.
(1995). Karl Theodore Dussik—Pioneer
in Ultrasound. , 70(12), 1136–. doi:
10.4065/70.12.1136.
[25]DUSSIK KT, DUSSIK F, WYT L.
Auf dem Wege zur Hyperphonographie
des Gehirnes [Towards
hyperphonography of the brain]. Wien
Med Wochenschr. 1947 Oct 4;97
(38-39):425-9. German. PMID:
18911482.
[26] Picard JD. Histoire de la
mammographie [History of
mammography]. Bull Acad Natl Med.
1998;182(8):1613-20. French. PMID:
10188307.
[27] Kalaf JM. Mammography: a history
of success and scientific enthusiasm.
Radiol Bras. 2014;47(4):VII-VIII. doi:
10.1590/0100-3984.2014.47.4e2
[28] Trevena L. Cancer screening Pros,




[29] Biesheuvel C, Weige S, Heindel W.
Mammography Screening: Evidence,
History and Current Practice in
Germany and Other European





[31]Geisel J, Raghu M, Hooley R. The
Role of Ultrasound in Breast Cancer
14
Breast Cancer - Evolving Challenges and Next Frontiers
Screening: The Case for and Against
Ultrasound. Semin Ultrasound CT MR.
2018 Feb;39(1):25-34. doi: 10.1053/j.
sult.2017.09.006. Epub 2017 Sep 22.
PMID: 29317037.
[32] Raichand, S., Dunn, A.G., Ong, MS.
et al. Conclusions in systematic reviews
of mammography for breast cancer
screening and associations with review
design and author characteristics. Syst
Rev 6, 105 (2017). https://doi.org/
10.1186/s13643-017-0495-6
[33] The Independent UK Panel on
Breast Cancer Screening. The benefits
and harms of breast cancer screening: an
independent review. Lancet. 2012;380
(9855):1778–1786. doi:10.1016/
S0140-6736(12)61611-0.
[34] Biesheuvel C, Weigel S, Heindel W.
Mammography Screening: Evidence,
History and Current Practice in
Germany and Other European
Countries. Breast Care (Basel).
2011;6(2):104-109. doi:10.1159/
000327493.
[35] Román, M., Hofvind, S., von Euler-
Chelpin, M. et al. Long-term risk of
screen-detected and interval breast
cancer after false-positive results at
mammography screening: joint analysis
of three national cohorts. Br J
Cancer 2019; 120, 269–275 . https://doi.
org/10.1038/s41416-018-0358-5
[36]Henderson LM, Hubbard RA,
Sprague BL, Zhu W, Kerlikowske K.
Increased Risk of Developing Breast
Cancer after a False-Positive
Screening Mammogram. Cancer
Epidemiol Biomarkers Prev. 2015;24(12):
1882-1889. doi:10.1158/1055-9965.
EPI-15-0623
[37]McCann, J., Stockton, D. &
Godward, S. Impact of false-positive
mammography on subsequent screening
attendance and risk of cancer. Breast
Cancer Res 4, R11 (2002). https://doi.
org/10.1186/bcr455.
[38] Seigneurin, A., Exbrayat, C.,
Labarère, J. et al. Association of
diagnostic work-up with subsequent
attendance in a breast cancer screening
program for false-positive cases. Breast
Cancer Res Treat. 2011; 127, 221–228
#https://doi.org/10.1007/s10549-010-
1118-2
[39] Lynge E, Olsen AH, Fracheboud J,
Patnick J. Reporting of performance
indicators of mammography screening




[40]World Health Organization. WHO
Position Paper on Mammography
Screening, 2014. Available at: www.
paho.org/cancer
[41] Alexandraki I, Mooradian AD.
Barriers related to mammography use
for breast cancer screening among
minority women. J Natl Med Assoc.
2010 Mar;102(3):206-218. doi: 10.1016/
s0027-9684(15)30527-7. PMID:
20355350.
[42]Orji CC, Kanu C, Adelodun AI,
Brown CM. Factors that Influence
Mammography Use for Breast Cancer
Screening among African American
Women. J Natl Med Assoc. 2020 Dec;
112(6):578-592. doi: 10.1016/j.
jnma.2020.05.004. Epub 2020 Jul 5.
PMID: 32641257.
[43]Nelson H, Fu R, Cantor A, Pappas
M, Daeges M, Humphrey L.
Effectiveness of Breast Cancer
Screening: Systematic Review and
Meta-analysis to Update the 2009 U.S.
Preventive Services Task Force
Recommendation. Annals of Internal
Medicine. 2016;164(4):244. doi:
10.7326/M15-0969
[44] Fletcher S. Breast Cancer Screening:






[45]Houssami N. Overdiagnosis of
breast cancer in population screening:
does it make breast screening worthless?.
Cancer Biol Med. 2017;14(1):1-8. doi:
10.20892/j.issn.2095-3941.2016.0050
[46]Marmot MG, Altman DG, Cameron
DA, Dewar JA, Thompson SG, Wilcox
M. The benefits and harms of breast
cancer screening: an independent
review. Br J Cancer. 2013;108(11):
2205-2240. doi:10.1038/bjc.2013.177
[47] Puliti D, Miccinesi G, Paci E.
Overdiagnosis in breast cancer: design
and methods of estimation in
observational studies. Prev Med. 2011
Sep;53(3):131-133. doi: 10.1016/j.
ypmed.2011.05.012. Epub 2011 Jun 2.
PMID: 21658405.
[48] Puliti D, Duffy SW, Miccinesi G, de
Koning H, Lynge E, Zappa M, Paci E;
EUROSCREEN Working Group.
Overdiagnosis in mammographic
screening for breast cancer in Europe: a
literature review. J Med Screen. 2012;19
Suppl 1:42-56. doi: 10.1258/
jms.2012.012082. PMID: 22972810.
[49] Yamamuro M, Asai Y, Hashimoto
N, Yasuda N, Ozaki Y, Ishii K, Lee Y.
The effect of breast density on the
missed lesion rate in screening digital
mammography determined using an
adjustable-density breast phantom
tailored to Japanese women. PLoS One
2021. DOI: 10.1371/journal.
pone.0245060
[50] Ekpo EU, Alakhras M, Brennan P.
Errors in Mammography Cannot be
Solved Through Technology Alone.
Asian Pac J Cancer Prev. 2018;19(2):
291-301. Published 2018 Feb 26. doi:
10.22034/APJCP.2018.19.2.291
[51] Vilaprinyo E, Forné C, Carles M,
et al. Cost-effectiveness and harm-
benefit analyses of risk-based screening
strategies for breast cancer. PLoS One.
2014;9(2):e86858. Published 2014 Feb 3.
doi:10.1371/journal.pone.0086858
[52] Siu A. Screening for Breast Cancer:
U.S. Preventive Services Task Force
Recommendation Statement. Annals of
Internal Medicine. 2016;164(4):279.
[53] Breast Cancer Screening (PDQ®)–
Health Professional Version [Internet].
National Cancer Institute. 2021 [cited 10
February 2021]. Available from: https://
www.cancer.gov/types/breast/hp/breast-
screening-pdq#_15_toc
[54]Menezes GL, Knuttel FM,
Stehouwer BL, Pijnappel RM, van den
Bosch MA. Magnetic resonance imaging
in breast cancer: A literature review and
future perspectives. World J Clin Oncol.
2014;5(2):61-70. doi:10.5306/wjco.v5.
i2.61
[55]Mann RM, Kuhl CK, Kinkel K,
Boetes C. Breast MRI: guidelines from
the European Society of Breast Imaging.
Eur Radiol. 2008;18(7):1307-1318. doi:
10.1007/s00330-008-0863-7
[56]Mandelblatt JS, Stout NK, Schechter
CB, van den Broek JJ, Miglioretti DL,
Krapcho M, Trentham-Dietz A, Munoz
D, Lee SJ, Berry DA, van Ravesteyn NT,
Alagoz O, Kerlikowske K, Tosteson AN,
Near AM, Hoeffken A, Chang Y,
Heijnsdijk EA, Chisholm G, Huang X,
Huang H, Ergun MA, Gangnon R,
Sprague BL, Plevritis S, Feuer E, de
Koning HJ, Cronin KA. Collaborative
Modeling of the Benefits and Harms
Associated With Different U.S. Breast
Cancer Screening Strategies. Ann Intern
Med. 2016 Feb 16;164(4):215-225. doi:
10.7326/M15-1536.
[57]Nothacker M, Duda V, Hahn M,
et al. Early detection of breast cancer:
benefits and risks of supplemental
breast ultrasound in asymptomatic
women with mammographically dense
breast tissue. A systematic review. BMC
Cancer. 2009;9:335. Published 2009 Sep
20. doi:10.1186/1471-2407-9-33
[58] Yuan, WH., Hsu, HC., Chen, YY.
et al. Supplemental breast
16
Breast Cancer - Evolving Challenges and Next Frontiers
cancer-screening ultrasonography in
women with dense breasts: a systematic
review and meta-analysis. Br J Cancer
123, 673–688 (2020). https://doi.org/
10.1038/s41416-020-0928-1
[59]Wang J, Zheng S, Ding L, et al. Is
Ultrasound an Accurate Alternative for
Mammography in Breast Cancer
Screening in an Asian Population? A
Meta-Analysis. Diagnostics (Basel).
2020;10(11):985. Published 2020 Nov
21. doi:10.3390/diagnostics1011098
[60] Yuan, WH., Hsu, HC., Chen, YY.
et al. Supplemental breast cancer-
screening ultrasonography in women
with dense breasts: a systematic review
and meta-analysis. Br J Cancer 123, 673–
688 (2020). https://doi.org/10.1038/
s41416-020-0928-1
[61]Health Quality Ontario. Ultrasound
as an Adjunct to Mammography for
Breast Cancer Screening: A Health
Technology Assessment. Ont Health
Technol Assess Ser. 2016;16(15):1-71.
Published 2016 Jul 1
[62]McKinney, S.M., Sieniek, M.,
Godbole, V. et al. International
evaluation of an AI system for breast
cancer screening. Nature 577, 89–94
(2020). https://doi.org/10.1038/
s41586-019-1799-6
[63] Lång, K., Hofvind, S., Rodríguez-
Ruiz, A. et al. Can artificial intelligence
reduce the interval cancer rate in
mammography screening?. Eur Radiol
(2021). https://doi.org/10.1007/
s00330-021-07686-3
[64]Ongena Y., Yakar D, Haan M., &
KweeT. Artificial intelligence in
screening mammography: A population
survey of women’s preferences. Journal
of the American College of Radiology.
2021, 18(1), 79-86. doi:10.1016/j.
jacr.2020.09.042
17
Breast Cancer Screening
DOI: http://dx.doi.org/10.5772/intechopen.97570
